期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 64, 期 11, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00513-20
关键词
Mycobacterium tuberculosis; delamanid; resistance; mutations; drug resistance; natural polymorphism
资金
- Swiss National Foundation [153442, 310030_166687, 310030_188888, IZRJZ3_164171, IZLSZ3_170834, CRSII5_177163]
- U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Cancer Institute
- National Institute of Mental Health
- National Institute on Drug Abuse
- National Heart, Lung, and Blood Institute
- National Institute on Alcohol Abuse and Alcoholism
- National Institute of Diabetes and Digestive and Kidney Diseases
- Fogarty International Center
- National Library of Medicine [U01AI069907, U01AI069923, U01AI096299, U01AI069911, U01AI069918, U01AI069924, U01AI069919]
- Francis Crick Institute
- UKRI
- CRUK
- Wellcome Trust [FC0010218, 104803, 203135]
- Swiss National Science Foundation (SNF) [IZRJZ3_164171, IZLSZ3_170834, CRSII5_177163, 310030_188888, 310030_166687] Funding Source: Swiss National Science Foundation (SNF)
Mutations in the genes of the F420 signaling pathway of Mycobacterium tuberculosis complex, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, can lead to delamanid resistance. We searched for such mutations among 129 M. tuberculosis strains from Asia, South America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes. For 10 strains with mutations, we determined the MIC of delamanid. We found one strain from a delamanid-naive patient carrying the natural polymorphism Tyr29del (ddn) that was associated with a critical delamanid MIC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
